Guizhounli Pharmaceutical Co (SHSE:603439) ROC %: 10.48% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603439 Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
90 GF Score
Price ¥11.41
GF Value ¥14.70
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Guizhounli Pharmaceutical Co ROC %?

Guizhounli Pharmaceutical Co SHSE:603439 -1.98% 90 ROC % is 10.48% as of Mar. 2026. GuruFocus rates SHSE:603439 with a GF Score™ of 90/100 and a GF Value™ of ¥14.70 (Modestly Undervalued). The stock has 10 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Guizhounli Pharmaceutical Co's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 10.48%.

As of today (2026-07-16), Guizhounli Pharmaceutical Co's WACC % is 10.62%. Guizhounli Pharmaceutical Co's ROC % is 6.94% (calculated using TTM income statement data). Guizhounli Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Guizhounli Pharmaceutical Co  (SHSE:603439) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Guizhounli Pharmaceutical Co's WACC % is 10.62%. Guizhounli Pharmaceutical Co's ROC % is 6.94% (calculated using TTM income statement data). Guizhounli Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Guizhounli Pharmaceutical Co ROC % Related Terms


Guizhounli Pharmaceutical Co ROC % Historical Data

* Premium members only.

The historical data trend for Guizhounli Pharmaceutical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhounli Pharmaceutical Co ROC % Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.16 24.96 18.34 16.36 7.20

Guizhounli Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.24 6.37 -0.46 21.10 10.48
SHSE:603439
90GF Score
Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guizhounli Pharmaceutical Co ROC % Calculation

Guizhounli Pharmaceutical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=198.695 * ( 1 - 28.94% )/( (1887.124 + 2033.811)/ 2 )
=141.192667/1960.4675
=7.20 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3192.108 - 807.194 - ( 497.79 - max(0, 1234.457 - 1797.985+497.79))
=1887.124

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2847.923 - 404.769 - ( 409.343 - max(0, 1037.171 - 1529.587+409.343))
=2033.811

Guizhounli Pharmaceutical Co's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=244.936 * ( 1 - 12.23% )/( (2033.811 + 2069.602)/ 2 )
=214.9803272/2051.7065
=10.48 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2847.923 - 404.769 - ( 409.343 - max(0, 1037.171 - 1529.587+409.343))
=2033.811

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2810.723 - 364.822 - ( 376.299 - max(0, 953.888 - 1498.801+376.299))
=2069.602

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 10.48% mean?
Guizhounli Pharmaceutical Co (SHSE:603439) has a ROC % of 10.48% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Guizhounli Pharmaceutical Co and its competitors.
Is Guizhounli Pharmaceutical Co's ROC % too high?
Guizhounli Pharmaceutical Co's current ROC % is 10.48%. The Drug Manufacturers industry median ROC % is 4.49. Guizhounli Pharmaceutical Co's value of 10.48% is 133.7% above this industry median. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's ROC % compare to ZTS and UTHR?
Guizhounli Pharmaceutical Co's ROC % of 10.48% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.49. Guizhounli Pharmaceutical Co's value of 10.48% is 133.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.49, based on 990 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhounli Pharmaceutical Co's current ROC % of 10.48% is 133.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Guizhounli Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhounli Pharmaceutical Co's current ROC % is 10.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.70, compared to a current price of ¥11.41 — trading 22.4% below its estimated fair value. The current ROC % is 10.48% and 133.7% above the Drug Manufacturers industry median of 4.49. Guizhounli Pharmaceutical Co's overall GF Score™ is 90/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current ROC % is 10.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?

Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥11.41 is trading 22.4% below its estimated GF Value™ of ¥14.70. GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603439:

  • ROC %: 10.48%
  • GF Value™: ¥14.70 vs. price of ¥11.41 (22.4% below fair value)
  • GF Score™: 90/100 with 10 warning signs
  • Industry Position: 133.7% above the Drug Manufacturers median

No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guizhounli Pharmaceutical Co Business Description

Address Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
90GF Score

Get the complete analysis for SHSE:603439

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.41
Price
¥14.70
GF Value